Spero Therapeutics (SPRO)

• Market cap: $38.2M
• 1 day: 3.95%
• 5 days: -5.66%
• 1 month: -1.44%
• 3 months: -14.81%
• 6 months: -42.03%
• Year to date: -36.67%
• 1 year: -55.87%
• 5 years: -94.30%
• 10 years: -94.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Employees: 32

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

9% more funds holding

Funds holding: 46 [Q3] → 50 (+4) [Q4]

5.92% more ownership

Funds ownership: 22.84% [Q3] → 28.76% (+5.92%) [Q4]

2% less capital invested

Capital invested by funds: $16.5M [Q3] → $16.1M (-$391K) [Q4]